Analyst Viewpoint
Vision impairment or blindness is a serious health issue across the globe. The third-most common cause of blindness is glaucoma. If detected early, the progression of glaucoma can be stabilized or prevented through medical and surgical therapy. Rise in awareness and screening campaigns about glaucoma and the efficacy of fixed-dose combination products, which can help prevent the need for complex eye surgeries in the near future, is likely to boost the glaucoma treatment market growth in the next few years.
Leading pharmaceutical players are investing significantly in the development of innovative technologies for early glaucoma detection and treatment owing to the large incidence of this disease. Furthermore, rise in approvals for intraocular pressure (IOP) lowering drugs is expected to create lucrative glaucoma treatment market opportunities for several manufacturers in the next few years.
Glaucoma is the degeneration of retinal ganglion cells and retinal nerve fiber layers, which may result in alteration in optical nerve head. Glaucoma is among the leading causes of irreversible blindness across the globe. Causes could include excessive smoking, vasospasm, age and frailty, myopia, systemic hypertension and hypotension, migraine, obstructive sleep apnea syndrome, increased IOP, and usage of steroids.
Latest innovation in glaucoma eye treatment, such as selective laser trabeculoplasty (SLT), medical imaging, optical coherence tomography (OCT), microinvasive glaucoma surgery (MIGS), visual fields, and progression analysis software are helping in the early diagnosis. This is expected to help in cure of glaucoma through over-the-counter fixed-combination dosages.
The post-COVID era changed the dynamics of screen time. Hybrid work models increased the time in front of screens, laptops, and smartphones. This is a key factor that fueled the incidences of glaucoma and consequently, augmented the demand for intraocular pressure management.
Currently, more than half of the patients suffering from glaucoma consume more than one drug at a time; however, a majority of patients do not adhere to the norms put forward by healthcare personnel regarding dosage of medications. Additionally, as there are no immediate negative consequences of this non-adherence, the patients do not get motivated to be concerned about compliance.
Increase in awareness regarding importance of bringing glaucoma under check has led to the development of fixed-dose combination products. Increase in demand for these products is expected to positively impact the global market scenario in the next few years.
As per the WHO, 2.2 billion people worldwide have a distance or near vision impairment. It further states that at around 1 billion out of these are suffering from vision impairment that could have been averted or at least addressed earlier. Furthermore, according to WHO, in 2020, glaucoma affected 76 million people worldwide.
The geriatric population is more prone to glaucoma; however, increase in screen time of smartphones and laptops amongst those aged 10 and above is also leading to glaucoma. As per the International Agency of the Prevention of Blindness, more than 2% of the U.S. population aged 40 and above has glaucoma. Therefore, increase in prevalence of glaucoma across the globe is anticipated to influence the future analysis of glaucoma treatment market during the forecast period.
North America accounted for the largest glaucoma treatment market share in 2022 due to the presence of well-established hospital infrastructure to diagnose and treat glaucoma. Timely diagnosis facilitates efficient treatment, as glaucoma is slowly progressing ailment.
Existence of favorable reimbursement scenario, subsidies offered by The National Health Services (NHS) for the treatment of glaucoma, rise in research on glaucoma treatment, and innovations in technology across the European Union are projected to drive Europe’s glaucoma treatment market size in the upcoming years.
Increase in number of geriatric population, growth in spending on healthcare in developing countries across Asia Pacific and surge in number of diabetic patients with a family history of glaucoma are key factors that are expected to drive the glaucoma treatment market development in Asia Pacific at a rapid pace during the forecast period.
The glaucoma treatment industry is highly consolidated owing to the presence of prominent players with significant global presence. Leading producers of glaucoma treatment drugs are focusing on the production of generic drugs, which is hampering the launch of new therapies, as exclusivity of banded drugs would be lost. A few prominent entities operating in the global market are Novartis AG, Pfizer, Inc., Merck & Co., Inc., Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd., Akorn, Inc., and Mobius Therapeutics, LLC.
Key players in the glaucoma treatment market report have been profiled based on various parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 6.3 Bn |
| Forecast (Value) in 2031 | US$ 9.1 Bn |
| Growth Rate (CAGR) | 4.3% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global market was valued at US$ 6.3 Bn in 2022
It is projected to grow at a CAGR of 4.3% from 2023 to 2031
Advent of fixed-dose combination products and rise in prevalence of glaucoma
In terms of sales channel, the hospital pharmacies segment held largest share in 2022
North America is estimated to dominate in the next few years
Novartis AG, Pfizer, Inc., Merck & Co., Inc., Bausch & Lomb Inc., Allergan Plc, Perrigo Plc, Teva Pharmaceutical Industries Ltd., Akorn, Inc., and Mobius Therapeutics, LLC
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Glaucoma Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Glaucoma Treatment Market Analysis and Forecast, 2023–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Glaucoma Treatment Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2023–2031
6.3.1. Prostaglandin Analogs (PGAs)
6.3.2. Alpha Agonist
6.3.3. Beta Blockers
6.3.4. Cholinergic
6.3.5. Carbonic Anhydrase Inhibitors
6.3.6. Combined Medications
6.4. Market Attractiveness Analysis, by Product Type
7. Global Glaucoma Treatment Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2023–2031
7.3.1. Angle Closure Glaucoma (ACG)
7.3.2. Open Angle Glaucoma (OAG)
7.3.3. Secondary Glaucoma
7.3.4. Congenital Glaucoma
7.3.5. Other Indications
7.4. Market Attractiveness Analysis, by Indication
8. Global Glaucoma Treatment Market Analysis and Forecast, by Sales Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Sales Channel, 2023–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Sales
8.4. Market Attractiveness Analysis, by Sales Channel
9. Global Glaucoma Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2023–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Glaucoma Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Product Type, 2023–2031
10.3.1. Prostaglandin Analogs (PGAs)
10.3.2. Alpha Agonist
10.3.3. Beta Blockers
10.3.4. Cholinergic
10.3.5. Carbonic Anhydrase Inhibitors
10.3.6. Combined Medications
10.4. Market Value Forecast, by Indication, 2023–2031
10.4.1. Angle Closure Glaucoma (ACG)
10.4.2. Open Angle Glaucoma (OAG)
10.4.3. Secondary Glaucoma
10.4.4. Congenital Glaucoma
10.4.5. Other Indications
10.5. Market Value Forecast, by Sales Channel, 2023–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Sales
10.6. Market Value Forecast, by Country, 2023–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Product Type
10.7.2. By Indication
10.7.3. By Sales Channel
10.7.4. By Country
11. Europe Glaucoma Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Product Type, 2023–2031
11.3.1. Prostaglandin Analogs (PGAs)
11.3.2. Alpha Agonist
11.3.3. Beta Blockers
11.3.4. Cholinergic
11.3.5. Carbonic Anhydrase Inhibitors
11.3.6. Combined Medications
11.4. Market Value Forecast, by Indication, 2023–2031
11.4.1. Angle Closure Glaucoma (ACG)
11.4.2. Open Angle Glaucoma (OAG)
11.4.3. Secondary Glaucoma
11.4.4. Congenital Glaucoma
11.4.5. Other Indications
11.5. Market Value Forecast, by Sales Channel, 2023–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Sales
11.6. Market Value Forecast, by Country/Sub-region, 2023–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Indication
11.7.3. By Sales Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Glaucoma Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Product Type, 2023–2031
12.3.1. Prostaglandin Analogs (PGAs)
12.3.2. Alpha Agonist
12.3.3. Beta Blockers
12.3.4. Cholinergic
12.3.5. Carbonic Anhydrase Inhibitors
12.3.6. Combined Medications
12.4. Market Value Forecast, by Indication, 2023–2031
12.4.1. Angle Closure Glaucoma (ACG)
12.4.2. Open Angle Glaucoma (OAG)
12.4.3. Secondary Glaucoma
12.4.4. Congenital Glaucoma
12.4.5. Other Indications
12.5. Market Value Forecast, by Sales Channel, 2023–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Sales
12.6. Market Value Forecast, by Country/Sub-region, 2023–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Indication
12.7.3. By Sales Channel
12.7.4. By Country/Sub-region
13. Latin America Glaucoma Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Product Type, 2023–2031
13.3.1. Prostaglandin Analogs (PGAs)
13.3.2. Alpha Agonist
13.3.3. Beta Blockers
13.3.4. Cholinergic
13.3.5. Carbonic Anhydrase Inhibitors
13.3.6. Combined Medications
13.4. Market Value Forecast, by Indication, 2023–2031
13.4.1. Angle Closure Glaucoma (ACG)
13.4.2. Open Angle Glaucoma (OAG)
13.4.3. Secondary Glaucoma
13.4.4. Congenital Glaucoma
13.4.5. Other Indications
13.5. Market Value Forecast, by Sales Channel, 2023–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Sales
13.6. Market Value Forecast, by Country/Sub-region, 2023–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Indication
13.7.3. By Sales Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Glaucoma Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Product Type, 2023–2031
14.3.1. Prostaglandin Analogs (PGAs)
14.3.2. Alpha Agonist
14.3.3. Beta Blockers
14.3.4. Cholinergic
14.3.5. Carbonic Anhydrase Inhibitors
14.3.6. Combined Medications
14.4. Market Value Forecast, by Indication, 2023–2031
14.4.1. Angle Closure Glaucoma (ACG)
14.4.2. Open Angle Glaucoma (OAG)
14.4.3. Secondary Glaucoma
14.4.4. Congenital Glaucoma
14.4.5. Other Indications
14.5. Market Value Forecast, by Sales Channel, 2023–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Sales
14.6. Market Value Forecast, by Country/Sub-region, 2023–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Indication
14.7.3. By Sales Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Pfizer, Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Merck & Co., Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Bausch & Lomb Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Allergan Plc
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Perrigo Plc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Teva Pharmaceutical Industries Ltd.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Akorn, Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Mobius Therapeutics, LLC
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
List of Tables
Table 01: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 02: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 03: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031
Table 04: Global Glaucoma Treatment Market Size (US$ Mn) Forecast, by Region, 2023–2031
Table 05: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country, 2023–2031
Table 06: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 07: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 08: North America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031
Table 09: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 10: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 11: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 12: Europe Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031
Table 13: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 14: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 15: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 16: Asia Pacific Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031
Table 17: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 18: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 19: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 20: Latin America Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031
Table 21: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2031
Table 22: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Product Type, 2023–2031
Table 23: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Indication, 2023–2031
Table 24: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2023–2031
List of Figures
Figure 01: Global Glaucoma Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2031
Figure 02: Global Glaucoma Treatment Market Revenue (US$ Mn), by Product Type, 2022
Figure 03: Global Glaucoma Treatment Market Value Share, by Product Type, 2022
Figure 04: Global Glaucoma Treatment Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Glaucoma Treatment Market Value Share, by Indication, 2022
Figure 06: Global Glaucoma Treatment Market Revenue (US$ Mn), by Sales Channel, 2022
Figure 07: Global Glaucoma Treatment Market Value Share, by Sales Channel, 2022
Figure 08: Global Glaucoma Treatment Market Value Share, by Region, 2022
Figure 09: Global Glaucoma Treatment Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 11: Global Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023-2031
Figure 12: Global Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
Figure 13: Global Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
Figure 15: Global Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023-2031
Figure 16: Global Glaucoma Treatment Market Value Share Analysis, by Region, 2023 and 2031
Figure 17: Global Glaucoma Treatment Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 19: North America Glaucoma Treatment Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Glaucoma Treatment Market Value Share Analysis, by Country, 2023 and 2031
Figure 21: North America Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 22: North America Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
Figure 23: North America Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
Figure 24: North America Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 25: North America Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 26:North America Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031
Figure 27: Europe Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 28: Europe Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 30: Europe Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 31: Europe Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
Figure 32: Europe Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
Figure 33: Europe Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 34: Europe Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 35: Europe Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031
Figure 36: Asia Pacific Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 37: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 39: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 40: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
Figure 41: Asia Pacific Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
Figure 42: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 43: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 44: Asia Pacific Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031
Figure 45: Latin America Glaucoma Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 46: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 48: Latin America Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 49: Latin America Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
Figure 50: Latin America Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
Figure 51: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 52: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 53: Latin America Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031
Figure 54: Middle East & Africa Glaucoma Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 55: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
Figure 57: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Product Type, 2023 and 2031
Figure 58: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Indication, 2023 and 2031
Figure 59: Middle East & Africa Glaucoma Treatment Market Value Share Analysis, by Sales Channel, 2023 and 2031
Figure 60: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Product Type, 2023–2031
Figure 61: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Indication, 2023–2031
Figure 62: Middle East & Africa Glaucoma Treatment Market Attractiveness Analysis, by Sales Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Glaucoma Treatment Market
